These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20233881)

  • 1. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.
    Mitchell JB; Choudhuri R; Fabre K; Sowers AL; Citrin D; Zabludoff SD; Cook JA
    Clin Cancer Res; 2010 Apr; 16(7):2076-84. PubMed ID: 20233881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.
    Ma Z; Yao G; Zhou B; Fan Y; Gao S; Feng X
    Mol Med Rep; 2012 Oct; 6(4):897-903. PubMed ID: 22825736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
    Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
    Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
    Zabludoff SD; Deng C; Grondine MR; Sheehy AM; Ashwell S; Caleb BL; Green S; Haye HR; Horn CL; Janetka JW; Liu D; Mouchet E; Ready S; Rosenthal JL; Queva C; Schwartz GK; Taylor KJ; Tse AN; Walker GE; White AM
    Mol Cancer Ther; 2008 Sep; 7(9):2955-66. PubMed ID: 18790776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.
    Yang H; Yoon SJ; Jin J; Choi SH; Seol HJ; Lee JI; Nam DH; Yoo HY
    Biochem Biophys Res Commun; 2011 Mar; 406(1):53-8. PubMed ID: 21291864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.
    Xu H; Cheung IY; Wei XX; Tran H; Gao X; Cheung NK
    Int J Cancer; 2011 Oct; 129(8):1953-62. PubMed ID: 21154747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
    Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
    Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
    BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
    Liu B; Chen W; Li H; Li F; Jin X; Li Q
    Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Nishimura M; Oumi N; Kato M; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Kudoh A; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Jan; 24(1):61-9. PubMed ID: 24362713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
    Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling.
    Wang L; Wang Y; Chen A; Jalali A; Liu S; Guo Y; Na S; Nakshatri H; Li BY; Yokota H
    Int J Oncol; 2018 Sep; 53(3):1001-1012. PubMed ID: 30015873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.
    Aris SM; Pommier Y
    Cancer Res; 2012 Feb; 72(4):979-89. PubMed ID: 22189968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
    J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
    Wang Q; Fan S; Eastman A; Worland PJ; Sausville EA; O'Connor PM
    J Natl Cancer Inst; 1996 Jul; 88(14):956-65. PubMed ID: 8667426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
    Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
    J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
    Parsels LA; Qian Y; Tanska DM; Gross M; Zhao L; Hassan MC; Arumugarajah S; Parsels JD; Hylander-Gans L; Simeone DM; Morosini D; Brown JL; Zabludoff SD; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2011 Jun; 17(11):3706-15. PubMed ID: 21482692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
    Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
    J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.
    Wang JN; Che Y; Yuan ZY; Lu ZL; Li Y; Zhang ZR; Li N; Li RD; Wan J; Sun HD; Sun N; Puno PT; He J
    Toxicol Appl Pharmacol; 2019 Feb; 365():71-83. PubMed ID: 30633885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.
    Sarcar B; Kahali S; Prabhu AH; Shumway SD; Xu Y; Demuth T; Chinnaiyan P
    Mol Cancer Ther; 2011 Dec; 10(12):2405-14. PubMed ID: 21992793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.